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Between 2007 and 2010, the Netherlands experi-
enced one of the largest outbreaks of Q fever. Since 
asymptomatic Coxiella burnetii infection has been 
associated with maternal and obstetric complications, 
evidence about the effectiveness of routine screening 
during pregnancy in outbreak areas is needed. We per-
formed a clustered randomised controlled trial during 
the Dutch outbreak, in which 55 midwife centres were 
randomised to recruit pregnant women for an interven-
tion or control strategy. In both groups a serum sam-
ple was taken between 20 and 32 weeks of gestation. 
In the intervention group (n=536), the samples were 
analysed immediately by indirect immunofluores-
cence assay for the presence of IgM and IgG (phase I/
II) and treatment was given during pregnancy in case 
of an acute or chronic infection. In the control group 
(n=693), sera were frozen for analysis after delivery. 
In both groups 15% were seropositive. In the interven-
tion group 2.2% of the women were seropositive and 
had an obstetric complication, compared with 1.4% in 
the control group (Odds ratio: 1.54 (95% confidence 
interval 0.60-3.96)). During a large Q fever outbreak, 
routine C. burnetii screening starting at 20 weeks of 
gestation was not associated with a relevant reduction 
in obstetric complications and should therefore not be 
recommended. 
Introduction
Viral, bacterial and parasitic infections during preg-
nancy, such as human immunodeficiency virus, syphi-
lis and toxoplasmosis, are a threat to both maternal 
and foetal health, even if the infection is asympto-
matic. Routine screening for some of these infectious 
diseases is therefore recommended for all pregnant 
women [1]. Due to several outbreaks, the incidence of 
Q fever, a zoonosis caused by the bacterium Coxiella 
burnetii, has been increasing in the Netherlands and 
some other European countries since 2007 [2,3]. Most 
of the infected individuals are either asymptomatic or 
present with a mild influenza-like illness. However, 
C. burnetii may pose a serious threat to pregnant 
women because of the increased risk of chronic Q 
fever, often complicated by endocarditis [4-6]. In addi-
tion, both symptomatic and asymptomatic C. burnetii 
infection during pregnancy have been associated with 
obstetric complications due to placentitis, including 
preterm delivery, intrauterine growth restriction and 
foetal death [7,8]. Because most infected pregnant 
women remain asymptomatic [9], routine serological 
screening during an outbreak could be of great value to 
prevent chronic maternal infections and obstetric com-
plications, but evidence from randomised trials is lack-
ing. Since the Dutch Q fever outbreak has been unique 
in size, with over 3,500 cases over three years [10], we 
had the opportunity to perform a clustered randomised 
controlled trial (RCT) to assess the effectiveness of 
large-scale routine serological screening for C. burnetii 
infection of pregnant women during a Q fever outbreak.
Methods
We conducted a clustered RCT in which primary care 
midwife centres were randomised to recruit pregnant 
women either for the intervention or for the control 
group (Figure 1). 
The study was conducted according to the principles of 
the Declaration of Helsinki, and the study protocol was 
approved by the Medical Ethical Review Board of the 
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University Medical Center Groningen. All participants 
gave written informed consent.
The study was set in Q fever high-risk areas in the 
Netherlands. High-risk areas were defined as munici-
palities with a Q fever incidence of more than 50 cases 
per 100,000 inhabitants in 2009 or more than 20 
cases per 100,000 inhabitants in the first half of 2010, 
according to the official Dutch surveillance data [11].
Randomisation 
Randomisation was stratified by the number of goat 
farms in the municipality (up to seven or more than 
seven), a measure of the risk associated with contract-
ing a C. burnetii infection according to a study by van 
der Hoek et al. [12], and by the size of the midwife cen-
tre (up to 300 or more than 300 pregnant women under 
care per year). Since this was an open-label study, 
midwives, other healthcare workers, participants and 
the researchers were aware of the outcome of the 
randomisation. 
Inclusion and exclusion criteria for participants
Pregnant women, 18 years of age or older, with an esti-
mated date of delivery between 1 June and 31 December 
2010, supervised by a midwife in primary healthcare 
Figure 1
Flow chart of the study protocol, study on screening for Coxiella burnetii infection during pregnancy, the Netherlands, 2010 
(n=1,229)
EDD: estimated date of delivery; IC: informed consent; IFA: indirect immunofluorescence assay.
a  For the intervention group intensified serological follow-up and pregnancy monitoring with possible antibiotic treatment were performed 
during pregnancy under supervision of secondary healthcare. For the control group serological follow-up was performed after pregnancy in 
collaboration with the patients’ general practitioner.
Randomisation  Intervention group  Control group  
 
Seronegative  Seropositive  
Clinical outcome, quality of life, fatigue  
 
  
Intensified follow-upa  
Analysed immediately with IFA: 
IgM and IgG phase I and II 
Serum sample between 20 and   
32 weeks of gestation  
Invite pregnant women with EDD  
1 June – 31 December 2010                    
IC procedure  by researchers
Exclusion criteria:                            
- < 18 years                               
- Doesn’t understand Dutch      
- Previously Q fever positive 
- No Internet/email                                              
Invite pregnant women with EDD 
1 June – 31 December 2010                    
IC procedure  by researchers 
Serum sample between 20 and   
32 weeks of gestation  
Serum frozen at – 20 ⁰ C 
for analysis after delivery  
Midwife centres in Q fever 
high-risk areas 
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were eligible for inclusion. In the Netherlands, mid-
wives working in primary healthcare are only allowed 
to supervise low-risk, singleton pregnancies. Using 
this criterion, women with a known increased risk 
for complicated pregnancy outcome beforehand e.g. 
twin pregnancies or pregnant women with chronic ill-
nesses, were excluded. Moreover, women who did not 
have access to Internet or an email address were also 
excluded because data collection was web-based. In 
the Netherlands, 91% of the households have Internet 
access [13]. The remaining 9% consist of elderly or 
single occupants, so very little exclusion from this 
restriction was expected. In addition, women who were 
unable to understand Dutch, unable to give informed 
consent, or were already diagnosed with Q fever, were 
ineligible for participation in the study. Since (diag-
nostic) testing was not performed on a regular basis 
before the study, very little exclusion from this restric-
tion was expected also.
Intervention group
Participants in the intervention group were asked for a 
serum sample between 20 and 32 weeks of gestation 
to be screened for infection with C. burnetii. The sam-
ples were analysed immediately by indirect immuno-
fluorescence assay (IFA) in the laboratory of the Jeroen 
Bosch Hospital, ‘s-Hertogenbosch, the Netherlands. 
Both immunoglobulin (Ig)M and IgG against C. burnetii 
phase I and phase II antigens (Nine Mile strain) were 
measured according to the manufacturer’s instruc-
tions (Focus Diagnostics, Cypress, CA, USA). Each run 
included a positive and a negative control. For every 
positive sample the titre was determined to reduce the 
chance of false positivity. In line with the cut-off values 
used in the clinical setting for the diagnosis of Q fever 
in symptomatic patients, titres ≥1:32 were considered 
positive [14]. Whenever there was IgM seropositivity, 
follow-up was performed two to four weeks after the 
screening sample had been taken. A probable acute 
infection was defined as the presence of positive titres 
of IgM (phase I and/or II) in the first screening sample. 
A proven acute infection was defined as positive titres 
for IgM accompanied with (rising) titres of IgG phase 
I and/or II during follow-up. A previous infection was 
defined as the presence of only IgG (phase I and/or II) 
in the screening sample. A probable chronic C. burnetii 
infection was defined as an antibody titre of IgG phase 
I ≥ 1:1,024 [15]. 
In seronegative women, standard care was provided. In 
case of a (probable) acute or chronic C. burnetii infec-
tion, women were referred to an obstetrician and inten-
sified serological and obstetric follow-up according to 
the local hospital protocol took place. Antibiotic treat-
ment (cotrimoxazole (960 mg twice daily) or erythromy-
cin (500 mg twice daily to four times a day, depending 
on the term of pregnancy) for at least five weeks) was 
started in collaboration with the local medical microbi-
ologist in any case of a proven acute or chronic infec-
tion. In case of a previous infection, no treatment was 
started, but serological analysis was repeated in the 
third trimester of pregnancy to exclude reactivation or 
chronic infection. 
Control group
Women in the control group were also asked for a 
serum sample between 20 and 32 weeks of gestation. 
These samples were centrally stored in the laboratory 
of the Jeroen Bosch Hospital at -20⁰C and were ana-
lysed for antibodies against C. burnetii after delivery, 
as the intervention group. In this group, distinguishing 
a probable and proven acute infection was impossible 
since follow-up serology during pregnancy was not 
performed. In case of a positive test, the participant’s 
general practitioner was advised to perform an extra 
serological analysis after delivery to exclude a prob-
able chronic infection. 
Both groups
If symptoms compatible with Q fever occurred during 
pregnancy, these participants were advised to visit a 
physician for regular diagnostics.
Outcome measures
The primary endpoint of the study pertained to the 
individual level and was a composite measure of a 
maternal or obstetric complication in seropositive 
women. A maternal complication was defined as a 
serological profile suggesting a probable chronic infec-
tion. Obstetric complications included preterm delivery 
(defined as delivery <37 weeks of gestation), a child 
small for gestational age (defined as birth weight <10th 
percentile [16]), and perinatal mortality (defined as foe-
tal or neonatal death between 22 weeks of gestation 
and one week post partum). 
Secondary endpoints were the separate components 
of the composite measure and maternal fatigue and 
quality of life one month post partum. Fatigue was 
assessed using the ‘Shortened fatigue questionnaire’ 
[17]. Quality of life was assessed using the validated 
‘EQ5D questionnaire’ [18]. 
Sample size calculation
Since midwifery in primary healthcare follows strict 
protocols and serology was performed in one labora-
tory for all participants the presence of clustering in the 
infrequent primary outcome of the study was expected 
to be minimal. Therefore the sample size calculation 
was performed at the individual level. 
Based on the literature and pilot data from the 
Netherlands, we expected that 12% of pregnant women 
in the Q fever high-risk areas would be seropositive 
[19,20]. Of these, we estimated at least 25% would 
have one of the previously defined complications. 
Thus, 3% of all pregnant women in Q fever high-risk 
areas would meet the primary outcome. A reduction of 
the complication rate by at least 50% as a consequence 
of early detection through screening during preg-
nancy was defined as clinically relevant. We consid-
ered reductions smaller than 50% unlikely to trigger a 
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change in practice given the implications on healthcare 
resources. Based on these expectations, we estimated 
needing at least 3,400 participants with complete 
follow-up to achieve a statistical power of 80% (two-
sided α=0.05). 
Statistical methods
Data were analysed according to intention-to-screen 
principle. Baseline demographic information was 
summarised by group using frequencies with percent-
ages for categorical variables and means with stand-
ard deviations for continuous variables. Odds ratios 
(OR) and corresponding 95% confidence intervals (CI) 
were calculated using generalised linear mixed mod-
els (GLMM) to adjust for possible clustering effects. 
For continuous variables the mean difference with 
95% CI was calculated. For the primary endpoint also 
the crude OR with 95% CI was calculated using binary 
logistic regression analysis, to provide an indication 
of the extent of clustering. A two-sided p value of 
0.05 or less was defined as being statistically signifi-
cant. Statistical analyses were performed using R ver-
sion 12.1 and PASW Statistics version 18.0 (SPSS inc. 
Chicago, Illinois, USA).
Figure 2
Flow chart of the progress of clusters and participants, study on screening for Coxiella burnetii infection during pregnancy, 
the Netherlands, 2010 (n=1,229)
a  Size of the midwife centre according to the number of eligible pregnant women under care.
 
 
 
 
 
 
Allocation to intervention strategy (27 centres)  
Intervention received    
all centres, median sizea = 116 (range 10-250)  
3,150 eligible pregnant women   
 
Allocation to control strategy (28 centres)   
Intervention received   
all centres, median sizea = 134 (range 32-306)   
3,710 eligible pregnant women   
Excluded:   
Refused to participate (44 centres) 
Assessed for eligibility (99 midwife centres) 
Randomised (55 midwife centres)
Lost to follow-up 
0 centres 
2,551 (81%) women not willing to participate. 
From 63/599 (11%) participants no sample received 
      serology not performed.  
Lost to follow-up
0 centres 
2,961 (80%) women not willing to participate.
From 56/749 (8%) participants no sample received 
      serology not performed.
Analysed 
100% (536/536) of the participants with 
serology performed. 
Analysed 
100% (693/693) of the participants with 
serology performed.
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Results
Between March 16 and July 17, 2010, 55 of the 99 eli-
gible midwife centres were willing to participate and 
were randomised: 27 to the intervention and 28 to 
the control strategy (Figure 2). In total, these centres 
supervised 6,860 eligible pregnant women of whom 
1,348 (20%) signed informed consent. Among these 
women a blood sample was collected for 1,229 partici-
pants: 536 participants (44%) in the intervention group 
and 693 (56%) in the control group. At the moment 
of screening, none of the participants suffered from 
clinical signs of symptomatic Q fever [4], such as pneu-
monia or hepatitis. 
Of 119 participants no blood sample was received, 
either because they forgot to give a sample or because 
the sample was lost. These women were excluded 
from the analysis since the primary outcome measure 
could not be determined. Of 104 participants in the 
intervention group and 196 participants in the con-
trol group, the sample was taken outside the protocol 
period, i.e. before 20 weeks of gestation (n=7 and n=5, 
Table 1
Baseline characteristics of the clusters (n=55) and participants, study on screening for Coxiella burnetii infection during 
pregnancy, the Netherlands, 2010 (n=1,229)
Intervention group (%) Control group (%)
Midwife centre characteristics
Number 27 28
Size
≤300 women per year 14 (52) 13 (46)
>300 women per year 13 (48) 15 (54)
Goat farms in municipality
≤7 13 (48) 14 (50)
>7 14 (52) 14 (50)
Participant characteristics
Number 536 693
Age (in years) mean± SD 31.9 ± 3.8 31.7 ± 3.7
Nulliparous 252 (47) 295 (43)
Ethnic origin non-westerna 14 (2.6) 12 (1.7)
Level of educationb
Low 29 (5.4) 49 (7.1)
Medium 177 (33) 228 (33)
High 319 (60) 411 (59)
Other/Unknown 11 (2.1) 5 (0.7)
Maternal smoking during pregnancy 54 (10) 54 (7.8)
Body mass index (kg/m2) mean± SDc 23.8 ± 3.7 24.1 ± 4.0
Primary hypertension 5 (0.9) 3 (0.4)
Hypothyroidism 6 (1.1) 11 (1.6)
History of preterm delivery 20 (3.7) 24 (3.5)
History of miscarriaged
None 411 (77) 550 (79)
One 97 (18) 115 (17)
Repeated 27 (5.0) 27 (3.9)
Gestational age (weeks) moment of sampling mean± SD 28.7 ± 4.7 29.9 ± 4.8
Coxiella burnetii seropositive 82 (15) 101 (15)
a  Non-western is defined as any ethnic background other than Western-Europe, North-American or Australian.   
b  Low: no formal education, primary school, lower-middle secondary school and lower professional school; medium: medium professional 
school and higher secondary school; high: higher professional school and university.
c  Prior to pregnancy.
d  n=535 for intervention group and n=692 for control group.
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Table 2
Complications in seropositive participants, study on screening for Coxiella burnetii infection during pregnancy, the 
Netherlands, 2010 (n=1,229)
Intervention group Control group
Unadjusted ORa 
(95% CI) P value
a Adjusted
ORb (95% CI) P value
bTotal
n=536 
(%)
Seropositives
n=82
(%)
Total
n=693 
(%)
Seropositives
n=101
(%)
Overall complicationc 12 (2.2) 12 (14.6) 10 (1.4) 10 (9.9) 1.56(0.67-3.65) 0.30
1.54
(0.60-3.96) 0.37
Preterm delivery 8 (1.5) 8 (9.8) 5 (0.7) 5 (5.0) 2.09(0.68-6.41) 0.20
1.80
(0.37-8.72) 0.47
Small for gestational age 4 (0.7) 4 (4.9) 5 (0.7) 5 (5.0) 1.04(0.28-3.87) 0.96
1.04
(0.28-3.87) 0.96
Perinatal mortality 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) Not applicable
CI: confidence interval; OR: odds ratio.
a  Crude odds ratio and p value calculated with binary logistic regression analysis.
b  Odds ratio and p value calculated with generalised linear mixed models, taking into account a clustering effect.
c  Primary outcome measure.
Table 3
Fatigue and quality of life one month post partum for all participants, study on screening for Coxiella burnetii infection 
during pregnancy, the Netherlands, 2010 (n=1,229)
Intervention 
group
n=536 (%)
Control group
n=693 (%) OR (95% CI)
a Mean differencea
(95% CI) P value
a
Fatigue score mean±SDb 14.6 ± 5.7 13.5 ± 5.5 NA 1.08 [0.43-1.72] <0.001
Quality of Lifec
Mobility ≥ 2 58 (12) 86 (14) 0.86 (0.60-1.23) NA 0.42
Self-care ≥ 2 3 (0.6) 3 (0.5) 1.31 (0.26-6.50) NA 0.75
Usual activities ≥ 2 74 (15) 99 (16) 0.97 (0.70-1.35) NA 0.85
Pain/discomfort ≥ 2 132 (27) 179 (28) 0.94 (0.72-1.24) NA 0.68
Anxiety/depression ≥ 2 27 (5.5) 38 (6.0) 0.92 (0.56-1.53) NA 0.75
EQ VAS±d 80.1 ± 11.6 81.4 ± 12.1 NA 1.18 (-0.39-2.75) 0.14
CI: confidence interval; NA: not applicable; OR: odds ratio.
a  Odds ratio, mean difference and p value calculated with generalised linear mixed  models, taking into account a clustering effect.
b  n=506 and 662 for the intervention and control group, respectively. Range of the score from 4 (not fatigue) to 28 (extreme fatigue).
c  First part of the ‘EQ5D’ questionnaire, n=488 and 636 for the intervention and control group, respectively. Score of 1=no problems, 2= with 
any problems, 3=with major problems. 
d  Second part of the ‘EQ5D’ questionnaire, self-reported health score on a scale from 0 to 100, score of 100=best imaginable health state, 
score 0= worst imaginable health state. Participants with a score lower than 11 were excluded (n=30), since a mistake while filling out was 
assumed.
7www.eurosurveillance.org
respectively) or after 32 weeks of gestation (n=97 and 
n=191). However, there was no difference in the base-
line and outcome variables between the participants 
with and without this protocol deviation (data not pre-
sented, available from authors on request), hence they 
were included in the analysis.
Baseline characteristics
Baseline characteristics are shown in Table 1. The 
mean gestational age at the time of sampling was 28.7 
weeks for the intervention group and 29.9 weeks for 
the control group. Fifteen per cent of the women in 
both groups were seropositive for C. burnetii in the 
first sample taken. Fifty-two of the 1,229 participants 
had a probable acute infection: 30 (5.6%) in the inter-
vention group and 22 (3.2%) in the control group; 131 
participants had a previous infection: 52 (9.7%) in the 
intervention group and 79 (11.4%) in the control group. 
After follow-up, seven women in the intervention group 
(1.3%) were confirmed as having an acute C. burnetii 
infection and antibiotic treatment was started at a 
median stage of pregnancy of 28 weeks (range 22-36 
weeks) for a duration of one to five weeks, depending 
on the serological follow-up and term of pregnancy. 
In the other 23 patients (77%) with a probable acute 
infection, follow-up serology ruled out this suspicion 
and was consistent with a previous infection. Follow-up 
showed no cases of probable maternal chronic infec-
tions in either of the two groups, so only obstetric 
complications in seropositive women were recorded 
as an endpoint. None of the women in the intervention 
or control group were treated with antibiotics during 
pregnancy for symptomatic Q fever.
Primary endpoint
For all the participants the primary outcome measure 
was available. There was no difference in the primary 
endpoint between the intervention and the control 
group (Table 2); the risk estimate obtained from the 
clustered analysis for an obstetric complication in 
seropositive women in the intervention group com-
pared with the control group was 1.54 (95% CI 0.60-
3.96). The non-clustered analysis showed a similar 
OR of 1.56 (95% CI 0.67-3.65). There were six cases of 
perinatal mortality: four foetal deaths and two early 
neonatal mortalities. For all of them the mothers were 
seronegative.
Secondary endpoints
Analyses of the separate components of the compos-
ite measure showed that the difference in the primary 
endpoint in favour of the control group, though non-
significant, seemed to be the result of a small differ-
ence in the risk of preterm delivery (Table 2). 
The fatigue score one month post partum was approx-
imately 1 point higher in the intervention group 
compared with the control group (14.6 versus 13.5, 
p<0.001). Quality of life did not differ between the two 
groups (Table 3).
Explorative analysis showed that C. burnetii seroposi-
tivity during pregnancy, even when the cut-off titre for 
seropositivity was increased to ≥1:64 (data not shown), 
Table 4
Pregnancy outcome for seropositive versus seronegative participantsa, study on screening for Coxiella burnetii infection 
during pregnancy, the Netherlands, 2010 (n=1,229)
Seropositive
n=183 (%)
Seronegative 
n=1,046 (%) OR (95% CI)
b Mean differenceb 
(95% CI) P value
b
Gestational age at delivery (in weeks) mean±SD 39.6 ± 1.8 39.7 ± 1.7 NA 0.12 (-0.15-0.38) 0.38
Preterm delivery <37 weeks 13 (7.1) 58 (5.5) 1.30 (0.70-2.43) NA 0.41
Preterm delivery <34 weeks 3 (1.6) 13 (1.2) 1.32 (0.37-4.69) NA 0.66
Birth weight (in grams) mean±SD 3,512 ± 527 3,507 ± 546 NA 4.8 (-81-90) 0.91
Small for gestational age 9 (4.9) 78 (7.5) 0.64 (0.32-1.30) NA 0.22
Perinatal mortality 0 (0.0) 6 (0.6) NA 0.60c
Overall complicationd 22 (12) 133 (13) 0.94 (0.58-1.52) NA 0.79
CI: confidence interval; NA: not applicable; OR: odds ratio.
a  Using a cut-off titre of ≥1:32
b  Odds ratio, mean difference and p value calculated with generalised linear mixed models, taking into account a clustering effect.
c  Calculated with Fisher’s exact test, since generalised linear mixed models could not provide a p value.
d  Composite measure of any preterm delivery, small for gestational age, or perinatal mortality.
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was not associated with gestational age at delivery, 
birth weight or any of the defined obstetric complica-
tions (Table 4). Of the seven women in the intervention 
group with an acute infection, two delivered preterm 
and one delivered a child small for gestational age. 
Discussion
We showed that, during a Q fever outbreak, large-scale 
routine serological screening for C. burnetii infection 
during pregnancy starting at 20 weeks of gestation 
seemed not to be associated with a relevant reduc-
tion in obstetric complications in seropositive women. 
Therefore, our data do not support such a preventive 
programme. This result was due to the low incidence 
of acute C. burnetii infection (1.3%), the absence of 
patients with a probable chronic infection and the fact 
that C. burnetii seropositivity was not associated with 
adverse pregnancy outcomes. 
Surprisingly, we observed that participants of the inter-
vention group had a somewhat higher fatigue score 
one month post partum than controls. Although the 
clinical relevance may be questionable, other screen-
ing strategies for infectious diseases during pregnancy 
have shown that screening for, and therefore aware-
ness of, infectious diseases may induce negative psy-
chological effects [21]. Importantly, despite the fact 
that our study was performed in a Q fever high-risk 
area and participation of midwife centres was satisfac-
tory (56%), the participation rate of pregnant women 
was unexpectedly low (20%). Although it’s likely that 
this low percentage reflects a reluctance to take part in 
a randomised controlled trial, this might also indicate 
that the acceptance of such a preventive programme 
among this group might not be straightforward. From 
an earlier study on this topic we learned that women’s 
appraisal of programme efficacy and convenience, 
their knowledge about the disease and perceived 
Q fever risk is crucial for their intended programme 
uptake [22].
Since three out of seven women with an acute C. bur-
netii infection in the intervention group had a compli-
cation, monitoring of pregnant women diagnosed with 
Q fever is still advisable and counselling about treat-
ment should be performed. Further studies on monitor-
ing and treatment, especially of symptomatic infected 
pregnant women, are needed.   
Strengths and limitations
A major strength of our study is that it is the first ran-
domised, prospective study in a community based 
- non-selected - pregnant population focusing on the 
effectiveness of routine screening for C. burnetii infec-
tion. Since the Dutch Q fever outbreak between 2007 
and 2010 was unique in its magnitude and duration, 
we had the opportunity to perform this study in a 
high-risk area. However, probably due to the drastic 
veterinary measures taken by the Dutch government, 
the incidence of acute C. burnetii infections steeply 
declined since 2010 [10]. Inclusion of participants after 
the second half of 2010 would not have been informa-
tive and was perceived as unethical. Therefore, we did 
not reach our projected number of participants, which 
increases the risk of a type II error. However, this risk 
seems to be minimal, because the lower estimate of 
the 95% CI of the primary outcome (OR 0.60) precludes 
the a priori defined 50% risk reduction in relevant 
outcomes. 
 There are also some further limitations to address. 
In this study screening started at 20 weeks of gesta-
tion. There are two main reasons why we chose this 
design. First of all, we aimed to avoid treatment with 
a drug (cotrimoxazole) that is not completely investi-
gated during the most vulnerable phase of pregnancy 
[23]. Earlier screening and withholding treatment until 
20 weeks of gestation was perceived as unethical and 
therefore not an option. Secondly, at 20 weeks of ges-
tation pregnant women could combine the venepunc-
ture for this study with a structural ultrasound, which 
is offered to all pregnant women in the Netherlands. 
With this we intended to increase the participation 
rate. Because of this design, screening in the first tri-
mester of pregnancy is still untested, and effective-
ness of such a strategy cannot be excluded. However, 
a recent Danish study showed no association between 
C. burnetii infection and spontaneous abortion up to 22 
weeks of gestation [24], indicating that screening ear-
lier in pregnancy would probably also be ineffective.
Given that 44% of the eligible midwife centres and 
80% of the eligible pregnant women were not willing 
to participate, it may not be possible to generalise the 
results. However, since major patient characteristics 
such as maternal age and proportion of nulliparous 
women are comparable with other large population 
based cohort studies from the Netherlands [25,26], we 
believe the degree of selection bias is minimal and our 
results are applicable to other Q fever outbreaks similar 
to the one in the Netherlands. Nevertheless pregnant 
women with a non-western ethnicity were underrepre-
sented in our study population so our results should 
be interpreted with caution for this group, especially 
because it is known that the seroprevalence in preg-
nant women with a non-Dutch ethnic background is 
higher [27]. 
In the 119 women who signed informed consent, but 
from whom no blood sample was available, Q fever 
cases could have been missed. However, participant 
characteristics and complication rates in this group 
were similar to the group with a blood sample ana-
lysed; therefore the risk of selection bias seems to be 
low. 
Serological screening during pregnancy in general 
is challenging. A high rate of false-positive tests has 
been described, especially for IgM assays [28,29]. 
Furthermore, the specificity of tests may be low if the 
incidence of the disease is relatively low and the preva-
lence is relatively high. Of every positive sample the 
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titre was determined and we performed serological fol-
low-up of all IgM positive women to prevent treatment 
of false-positive acute cases. 
In contrast to our results, previous studies reported a 
strong association between undetected and untreated 
C. burnetii infection during pregnancy and complicated 
pregnancy outcome [7,8,30]. One explanation for this 
might be that in the previous non-randomised stud-
ies, selection bias could have led to an overestimation 
of the risks. Otherwise, differences in pathogenic-
ity between different C. burnetii strains could exist. 
Genotyping of Dutch samples is ongoing [31]. Since in 
the Netherlands a relatively high number of chronic Q 
fever cases have been described in patients with aneu-
rysms [32], it could be hypothesised that the strains 
involved in the Dutch outbreak are highly virulent for 
people with underlying vascular diseases, while preg-
nant women are relatively protected [33]. However, 
further discussion on this topic is beyond the scope of 
this paper.
There are also studies in line with our results. In three 
large studies conducted in Q fever high-risk areas in 
Denmark, the Netherlands and France no association 
between seropositivity and complicated pregnancy 
outcome was found [24,27,34].
Conclusions
This clustered randomised controlled trial showed that 
15% of the pregnant women in a Q fever outbreak area 
were seropositive, but the incidence of acute C. burnetii 
infection was low. Although the broad confidence inter-
val did not exclude a small beneficial effect of screen-
ing, routine screening during pregnancy starting at 20 
weeks of gestation seems not to be associated with a 
relevant reduction of obstetric complications in sero-
positive women. Therefore, in the current setting, this 
study does not support such a preventive programme.
Acknowledgements 
The authors would like to thank Ms. Barbara C. Boer, Ms. 
Ilona Bosker and Ms. Anja B. Van den Hengel for their as-
sistance at the participants’ service desk and Mr. Petros 
Pechlivanoglou for statistical support. Furthermore, the au-
thors gratefully thank all midwives, residents, obstetricians, 
paediatricians and medical microbiologists of the participat-
ing centres for their help in patient recruitment and/or data 
collection. 
This work was financially supported by ZonMw, 
The Netherlands Organisation for Health Research 
and Development; programme ‘’Effectiviteits- en 
Doelmatigheidsonderzoek’’ (grant number 125030014).
Trial registration: ClinicalTrials.gov, identifier NCT01095328
http://clinicaltrials.gov/ct2/show/NCT01095328?term=q+fe
ver+pregnancy&rank=1 
Conflict of interest 
None declared.
Authors’ contributions
JMM participated in the design of the study, performed the 
study, analysed and interpreted the data and drafted the 
manuscript; ACAPL participated in the design of the study as 
an expert on laboratory testing and performed the diagnos-
tic analyses; CJCMH participated in the design of the study 
as an expert on obstetric care; JCEM was responsible for the 
logistics surrounding laboratory testing; PMS participated in 
the design of the study as an expert on laboratory testing 
and performed the diagnostic analyses; WvdH participated 
in the design of the study as an expert on national public 
healthcare and performed the data on Q fever risk areas; AR 
participated in the design of the study as an expert on local 
health care in the most affected areas of the Netherlands; 
EdV participated in the design of the study as an expert on 
paediatrics; RPS participated in the design of the study as 
an expert on epidemiology; JGA participated in the design 
of the study as an expert on obstetric care and supervised 
the analysis and report; EH initiated and designed the study, 
wrote the grant application, and supervised the data collec-
tion, analysis and report. All authors revised the draft manu-
script and approved the final manuscript.
10 www.eurosurveillance.org
References
1. Schrag SJ, Arnold KE, Mohle-Boetani JC, Lynfield R, Zell 
ER, Stefonek K, et al. Prenatal screening for infectious 
diseases and opportunities for prevention. Obstet 
Gynecol. 2003;102(4):753-60. http://dx.doi.org/10.1016/
S0029-7844(03)00671-9 
2. European Centre for Disease Prevention and Control (ECDC). 
Annual epidemiological report on communicable diseases in 
Europe 2010. Stockholm: ECDC. 2010; Available from: http://
www.ecdc.europa.eu/en/publications/Publications/1011_
SUR_Annual_Epidemiological_Report_on_Communicable_
Diseases_in_Europe.pdf 
3. Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, 
Weers-Pothoff G, Timen A, et al. Large ongoing Q fever 
outbreak in the south of The Netherlands, 2008. Euro 
Surveill. 2008;13(31):pii=18939. Available from: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=18939 
4. Parker NR, Barralet JH, Bell AM. Q fever. Lancet. 
2006;367(9511):679-88. http://dx.doi.org/10.1016/
S0140-6736(06)68266-4 
5. Hartzell JD, Wood-Morris RN, Martinez LJ, Trotta RF. Q fever: 
epidemiology, diagnosis and treatment. Mayo Clin Proc. 
2008;83(5):574-9. PMid:18452690. 
6. Raoult D, Marrie TJ, Mege JL. Natural history and 
pathophysiology of Q fever. Lancet Infect Dis. 2005;5(4):219-
26. http://dx.doi.org/10.1016/S1473-3099(05)70052-9 
7. Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A. Managing 
Q fever during pregnancy: the benefits of long-term 
cotrimoxazole therapy. Clin Infect Dis. 2007;45(5):548-55. 
http://dx.doi.org/10.1086/520661. PMid:17682987. 
8. Langley JM, Marrie TJ, Le Blanc JC, Almudevar A, Resch L, 
Raoult D. Coxiella burnetii seropositivity in parturient women 
is associated with adverse pregnancy outcomes. Am J Obstet 
Gynecol. 2003;189(1):228-32. http://dx.doi.org/10.1067/
mob.2003.448. PMid:12861167. 
9. Tissot-Dupont H, Vaillant V, Rey S, Raoult D. Role of sex, age, 
previous valve lesion and pregnancy in the clinical expression 
and outcome of Q fever after a large outbreak. Clin Infect 
Dis. 2007;44(2):232-7. http://dx.doi.org/10.1086/510389. 
PMid:17173223. 
10. Roest HI, Tilburg JJ, Van der Hoek W, Vellema P, van 
Zijderveld FG, Klaassen CH, et al. The Q fever epidemic in 
The Netherlands: history, onset, response and reflection. 
Epidemiol Infect 2011;139(1):1-12. http://dx.doi.org/10.1017/
S0950268810002268. PMid:20920383. 
11. National Institute for Public Health and the Environment. 
Gemelde Q-koortspatiënten 2007-2011. [Notified number of Q 
fever cases 2007-2011, incidence per municipality]. Bilthoven: 
RIVM; [Accessed Jun 2013]. Available from: http://www.rivm.nl/
dsresource?objectid=rivmp:180268&type=org&disposition=in
line&ns_nc=1 
12. Van der Hoek W, Meekelenkamp JC, Dijkstra F, Notermans DW, 
Bom B, Vellema P, et al. Proximity to goat farms and Coxiella 
burnetii seroprevalence among pregnant women. Emerg 
Infect Dis. 2011;17(12):2360-3. http://dx.doi.org/10.3201/
eid1712.110738. PMid:22172140. PMCid:3311170. 
13. Statistics Netherlands. No home internet access for 1.2 million 
Dutch people. Den Haag: Statistics Netherlands. 18 Dec 2008; 
Available from: http://www.cbs.nl/en-GB/menu/themas/vrije-
tijd-cultuur/publicaties/artikelen/archief/2008/2008-2641-wm.
htm?Languageswitch=on 
14. Meekelenkamp JC, Schneeberger PM, Wever PC, Leenders 
AC. Comparison of ELISA and indirect immunofluorescent 
antibody assay detecting Coxiella burnetii IgM phase II for 
the diagnosis of acute Q fever. Eur J Clin Microbiol Infect Dis. 
2012;31(6):1267-70. http://dx.doi.org/10.1007/s10096-011-
1438-0. PMid:21997772. 
15. Wegdam-Blans MC, Kampschreur LM, Delsing CE, Bleeker-
Rovers CP, Sprong T, van Kasteren ME, et al. Chronic 
Q fever: review of the literature and a proposal of new 
diagnostic criteria. J Infect. 2012;64(3):247-59. http://dx.doi.
org/10.1016/j.jinf.2011.12.014. PMid:22226692. 
16. Visser GH, Eilers PH, Elferink-Stinkens PM, Merkus HW, Wit 
JM. New Dutch reference curves for birthweight by gestational 
age. Early Hum Dev. 2009;85(12):737-44. http://dx.doi.
org/10.1016/j.earlhumdev.2009.09.008. PMid:19914013. 
17. Alberts M, Smets EMA, Vercoulen JHMM, Garssen B, 
Bleijenberg G. “Verkorte vermoeidheidsvragenlijst”: een 
praktisch hulpmiddel bij het scoren van vermoeidheid. 
[Shortened fatigue questionnaire: a practical aid in scoring 
fatigue]. Ned Tijdschr Geneeskd. 1997;141(31):1526-30. Dutch. 
PMid:9543741. 
18. Centre for Health Economics, University of York. The EuroQoL 
Group. EuroQol: A new facility for the measurement of 
health-related quality of life. Health Policy. 1990;16(3):199-
208. http://dx.doi.org/10.1016/0168-8510(90)90421-9. 
19. Karagiannis I, Schimmer B, Van Lier A, Timen A, Schneeberger 
P, Van Rotterdam B, et al. Investigation of a Q fever 
outbreak in a rural area of the Netherlands. Epidemiol 
Infect 2009;137(9):1283–94. http://dx.doi.org/10.1017/
S0950268808001908. PMid:19161644. 
20. Meekelenkamp JCE, Notermans DW, Rietveld A, Marcelis JH, 
Schimmer B, Reimerink JHJ, et al. Seroprevalence of Coxiella 
burnetii in pregnant women in the province of Noord-Brabant 
in 2007. Infectieziekten Bulletin. 2009;20(2):57-61. Dutch. 
21. Melville J, Sniffen S, Crosby R, Salazar L, Whittington W, 
Dithmer-Schreck D, et al. Psychosocial impact of serological 
diagnosis of herpes simplex virus type 2: a qualitative 
assessment. Sex Transm Infect. 2003;79(4):280-5. 
http://dx.doi.org/10.1136/sti.79.4.280. PMid:12902574. 
PMCid:1744709. 
22. Breteler JK, Oudhoff JP, Munster JM, Aarnoudse JG, van 
Steenbergen JE, Beaujean DJ. Risks, trust and knowledge: 
determinants of pregnant women’s decisions regarding 
participation in a future Q fever screening and treatment 
program during a large epidemic in The Netherlands. Prenat 
Diagn. 2011;31(8):814-20. http://dx.doi.org/10.1002/pd.2772. 
PMid:21717482. 
23. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. 
Folic acid antagonists during pregnancy and the risk of birth 
defects. N Engl J Med. 2000;343(22):1608-14. http://dx.doi.
org/10.1056/NEJM200011303432204. PMid:11096168. 
24. Nielsen SY, Hjøllund NH, Andersen AM, Henriksen TB, 
Kantsø B, Krogfelt KA, et al. Presence of antibodies against 
Coxiella burnetii and risk of spontaneous abortion: a nested 
case-control study. PLoS One. 2012;7(2):e31909. http://
dx.doi.org/10.1371/journal.pone.0031909. PMid:22363769. 
PMCid:3283715. 
25. Ravelli AC, Jager KJ, de Groot MH, Erwich JJ, Rijninks-van 
Driel GC, Tromp M, et al. Travel time from home to hospital 
and adverse perinatal outcomes in women at term in the 
Netherlands. BJOG 2011;118(4):457-65. http://dx.doi.
org/10.1111/j.1471-0528.2010.02816.x. PMid:21138515. 
26. Tromp M, Eskes M, Reitsma JB, Erwich JJ, Brouwers HA, 
Rijninks-van Driel GC, et al. Regional perinatal mortality 
differences in the Netherlands; care is the question. BMC 
Public Health. 2009;9:102. http://dx.doi.org/10.1186/1471-
2458-9-102. PMid:19366460. PMCid:2674436. 
27. Van der Hoek W, Meekelenkamp JCE, Leenders ACAP, Wijers N, 
Notermans DW, Hukkelhoven CW. Antibodies against Coxiella 
burnetii and pregnancy outcome during the 2007-2008 Q fever 
outbreaks in the Netherlands. BMC Infect Dis. 2011;11:44. 
http://dx.doi.org/10.1186/1471-2334-11-44. PMid:21314933. 
PMCid:3042933. 
28. De Carolis S, Santucci S, Botta A, Garofalo S, Martino C, 
Perrelli A, et al. False-positive IgM for CMV in pregnant women 
with autoimmune disease: a novel prognostic factor for poor 
pregnancy outcome. Lupus 2010;19(7):844-9. http://dx.doi.
org/10.1177/0961203310361350. PMid:20305050. 
29. Jones JL, Krueger A, Schulkin J, Schantz PM. Toxoplasmosis 
prevention and testing in pregnancy, survey of obstetrician–
gynaecologists. Zoonoses Public Health. 2010;57(1):27-
33. http://dx.doi.org/10.1111/j.1863-2378.2009.01277.x. 
PMid:19744302. 
30. Stein A, Raoult D. Q fever during pregnancy: a public health 
problem in Southern France. Clin Infect Dis. 1998;27(3):592-6. 
http://dx.doi.org/10.1086/514698 
31. Huijsmans CJ, Schellekens JJ, Wever PC, Toman R, Savelkoul 
PH, Janse I, et al. SNP-genotyping of a Coxiella burnetii 
outbreak in the Netherlands. Appl Environ Microbiol. 
2011;77(6):2051-7. http://dx.doi.org/10.1128/AEM.02293-10. 
PMid:21257816. PMCid:3067327. 
32. Wever PC, Arts CH, Groot CA, Lestrade PJ, Koning OH, Renders 
NH. Screening for chronic Q fever in symptomatic patients with 
an aortic aneurysm or prosthesis. Ned Tijdschr Geneeskd. 
2010;154:A2122. Dutch. PMid:20699030. 
33. Angelakis E, Million M, D’Amato F, Rouli L, Richet H, Stein A, 
et al. Q fever and pregnacy: disease, prevention, and strain 
specificity. Eur J Clin Microbiol Infect Dis. 2013;32(3):361-8. 
http://dx.doi.org/10.1007/s10096-012-1750-3. PMid:23052984. 
34. Rey D, Obadia Y, Tissot-Dupont H, Raoult D. Seroprevalence 
of antibodies to Coxiella burnetii among pregnant 
women in South Eastern France. Eur J Obstet Gynecol 
Reprod Biol. 2000;93(2):151-6. http://dx.doi.org/10.1016/
S0301-2115(00)00276-1
